CRBU - Caribou stock plunges 30% amid study update Evercore downgrade
2024-06-03 10:02:56 ET
More on Caribou Bioscience
- Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
- Caribou Biosciences GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M
- Caribou Biosciences received IND clearance from FDA for its lupus treatment
- Seeking Alpha’s Quant Rating on Caribou Bioscience
- Historical earnings data for Caribou Bioscience